Stay updated on AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial
Sign up to get notified when there's something new on the AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial page.

Latest updates to the AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial page
- Check5 days agoChange DetectedA banner announces that NIH is transitioning to use “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI), with both terms appearing during the transition.SummaryDifference1%

- Check12 days agoChange DetectedThe footer revision changed from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden message.SummaryDifference0.2%

- Check19 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check40 days agoChange DetectedThe page now renders a 403 Forbidden error page instead of the study content, replacing the study details with a generic error screen. This blocks access to the trial information and navigation, effectively making the page unusable for viewing the study record.SummaryDifference21%

- Check61 days agoChange DetectedA US NIH grant/contract funding line was added to the study's identifiers. The page revision was updated to v3.6.6, replacing v3.6.5, indicating an updated study record.SummaryDifference0.1%

- Check82 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5. This reflects a minor update to the page's template or documentation without altering the displayed study details.SummaryDifference0.0%

Stay in the know with updates to AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AZD8701 & Durvalumab in Advanced Solid Tumours Clinical Trial page.